-
ADMA Biologics (ADMA) Misses Q2 EPS by 1c
-
Increasing unusual put option volume: ADMA ASPN MSOS PR BE FLNC CVE GXO TAP AXON
-
ADMA Biologics (ADMA) Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
-
ADMA Biologics (ADMA) spreader of 3K contracts of April 19 and May 22 calls as share price up 4.3%
-
ADMA Biologics (ADMA) Issues Statement on Tariffs
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
ADMA Biologics (ADMA) PT Raised to $32 at Mizuho
-
Cantor Fitzgerald Reiterates Overweight Rating on ADMA Biologics (ADMA)
-
ADMA Biologics (ADMA) Tops Q4 EPS by 31c, Offers Guidance
-
Options with decreasing option implied volatility: MNKD AEHR AUR GME IRBT ADMA CONY
-
ADMA Biologics (ADMA) PT Raised to $28 at Mizuho
-
Mizuho Reiterates Outperform Rating on ADMA Biologics (ADMA)
-
ADMA Biologics (ADMA) call put ratio 1.6 calls to 1 put on active options volume of 16K contracts
-
Mizuho Reiterates Outperform Rating on ADMA Biologics (ADMA)
-
ADMA Biologics (ADMA) Tops Q3 EPS by 2c
-
H.C. Wainwright Reiterates Buy Rating on ADMA Biologics (ADMA)
-
Mizuho Healthcare Desk Distributes Comments on ADMA Biologics (ADMA) Weakness Post Call, Shares Down ~20%
-
ADMA Biologics (ADMA) to Join S&P SmallCap 600 Index
-
Zurn Elkay Water, Clear Secure, TG Therapeutics, others to join S&P SmallCap 600
-
ADMA Biologics (ADMA) Announces Partial Paydown of Revolving Credit Facility
-
ADMA Biologics (ADMA) PT Raised to $18 at H.C. Wainwright
-
ADMA Biologics (ADMA) Tops Q2 EPS by 5c ; Offers Guidance
-
ADMA Biologics (ADMA) PT Raised to $14 at Mizuho

